Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
A phase 3 trial of Mitoxantrone and Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.
Overview
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL is a phase 3 interventional study registered as NCT04668690 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 193 participants enrolled, started 2021-04-13 and due to reach its primary completion in 2027-12-30. Interventions recorded: Mitoxantrone Hydrochloride Liposome Injection and Chidamide.
Similar pages
not linked directly; found by shared links- TrialChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares CSPC Pharmaceutical Group and the tag pipeline.